Pharma

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The US Food and Drug Administration has approved Ilaris for the treatment of children and adults with cryopyrin-associated periodic syndrome, which includes a number of rare but life-long auto-inflammatory disorders with debilitating symptoms and limited treatment options. The FDA granted priority review to Ilaris based on its potential to meet an important clinical need for patients with CAPS.

Today in Drug/Product Approvals...keeping you current

Recombinant Human Erythropoietin, Epogin Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09

Synthon announces European approvals for Raloxifene
Synthon, 12/08/09

US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09